ST段抬高型心肌梗死伴多支冠状动脉病变患者的完全血运重建与多支血管PCI
该随机对照试验纳入STEMI且多支冠状动脉病变、罪犯病变PCI成功的患者,比较完全血运重建(对血管造影显著的非罪犯病变行PCI)与仅处理罪犯病变PCI。中位随访3年,完全血运重建组心血管死亡或心肌梗死发生率为7.8%,仅罪犯病变PCI组为10.5%(HR 0.74;95%CI 0.60~0.91;P=0.004);心血管死亡、心肌梗死或缺血驱动血运重建复合终点发生率分别为8.9%和16.7%(HR 0.51;95%CI 0.43~0.61;P<0.001)。无论非罪犯病变PCI计划时机如何,完全血运重建的获益一致。
要点
- STEMI伴多支病变且罪犯病变PCI成功后,完全血运重建组较仅罪犯病变PCI组心血管死亡或心肌梗死风险降低(HR 0.74;95%CI 0.60~0.91;P=0.004)。
- 完全血运重建组心血管死亡、心肌梗死或缺血驱动血运重建复合终点风险亦低于仅罪犯病变PCI组(HR 0.51;95%CI 0.43~0.61;P<0.001)。
- 完全血运重建的获益不受非罪犯病变PCI计划时机(住院期间或出院后)影响(交互作用P=0.62和P=0.27)。
- 中位随访3年,完全血运重建组第一复合终点发生率7.8%(158/2016),仅罪犯病变PCI组10.5%(213/2025)。
适用人群与场景
- ST段抬高型心肌梗死(STEMI)伴多支冠状动脉病变、且已成功行罪犯病变PCI的患者。
处置流程与药物剂量
- 完全血运重建策略:对血管造影显著的非罪犯病变行PCI;非罪犯病变PCI的时机可为住院期间或出院后(按随机化分层)。
研究设计与关键结果
- 随机对照试验,纳入STEMI伴多支冠状动脉病变且罪犯病变PCI成功的患者,随机分为完全血运重建组(n=2016)和仅罪犯病变PCI组(n=2025)。
- 中位随访3年,第一复合终点(心血管死亡或心肌梗死)完全血运重建组158/2016(7.8%)vs 仅罪犯病变PCI组213/2025(10.5%),HR 0.74(95%CI 0.60~0.91),P=0.004。
- 第二复合终点(心血管死亡、心肌梗死或缺血驱动血运重建)完全血运重建组179例(8.9%)vs 仅罪犯病变PCI组339例(16.7%),HR 0.51(95%CI 0.43~0.61),P<0.001。
- 两个复合终点的获益均不受非罪犯病变PCI计划时机影响(交互作用P=0.62和P=0.27)。
证据类型、等级与局限
- 证据类型:随机对照试验(COMPLETE试验,NCT01740479)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于STEMI伴多支冠状动脉病变且罪犯病变PCI成功的患者,完全血运重建在降低心血管死亡或心肌梗死以及心血管死亡、心肌梗死或缺血驱动血运重建风险方面优于仅罪犯病变PCI。
- 完全血运重建的获益不受非罪犯病变PCI计划时机(住院期间或出院后)影响。
指南或共识出处
- COMPLETE试验(ClinicalTrials.gov NCT01740479),由Canadian Institutes of Health Research等资助。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: In patients with ST-segment elevation myocardial infarction (STEMI), percutaneous coronary intervention (PCI) of the culprit lesion reduces the risk of cardiovascular death or myocardial infarction. Whether PCI of nonculprit lesions further reduces the risk of such events is unclear.
METHODS: We randomly assigned patients with STEMI and multivessel coronary artery disease who had undergone successful culprit-lesion PCI to a strategy of either complete revascularization with PCI of angiographically significant nonculprit lesions or no further revascularization. Randomization was stratified according to the intended timing of nonculprit-lesion PCI (either during or after the index hospitalization). The first coprimary outcome was the composite of cardiovascular death or myocardial infarction; the second coprimary outcome was the composite of cardiovascular death, myocardial infarction, or ischemia-driven revascularization.
RESULTS: At a median follow-up of 3 years, the first coprimary outcome had occurred in 158 of the 2016 patients (7.8%) in the complete-revascularization group as compared with 213 of the 2025 patients (10.5%) in the culprit-lesion-only PCI group (hazard ratio, 0.74; 95% confidence interval [CI], 0.60 to 0.91; P = 0.004). The second coprimary outcome had occurred in 179 patients (8.9%) in the complete-revascularization group as compared with 339 patients (16.7%) in the culprit-lesion-only PCI group (hazard ratio, 0.51; 95% CI, 0.43 to 0.61; P<0.001). For both coprimary outcomes, the benefit of complete revascularization was consistently observed regardless of the intended timing of nonculprit-lesion PCI (P = 0.62 and P = 0.27 for interaction for the first and second coprimary outcomes, respectively).
CONCLUSIONS: Among patients with STEMI and multivessel coronary artery disease, complete revascularization was superior to culprit-lesion-only PCI in reducing the risk of cardiovascular death or myocardial infarction, as well as the risk of cardiovascular death, myocardial infarction, or ischemia-driven revascularization. (Funded by the Canadian Institutes of Health Research and others; COMPLETE ClinicalTrials.gov number, NCT01740479.).
参考来源
- Mehta SR, Wood DA, Storey RF, et al. Complete Revascularization with Multivessel PCI for Myocardial Infarction. N Engl J Med. 2019. PMID: 31475795. doi:10.1056/NEJMoa1907775
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。